Upcoming FDA Advisory Committee meetings (sourced live from the Federal Register API), plus biotech-tagged tickers in the Framler universe with earnings in the next 30 days. Free, refreshed every 2 hours. Each ticker links to its full Framler analysis with Phase 3 trial scoring and pharma-stage classification.
FDA Advisory Committee meetings
Federal Register notices from the last 30 days. AdCom reviews precede most NDA / BLA approval decisions; binary outcomes for the sponsor.
Meeting 2026-09-23· Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee
Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-GRAIL, Inc. Galleri
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee (the Committee). The general function of the Committee i…
Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments
The Food and Drug Administration (FDA or the Agency) announces a forthcoming public advisory committee meeting of the Pediatric Advisory Committee (PAC). The general function of the committee is to provide advice and recommendations to FDA …
Filed 2026-07-24· Cellular, Tissue, and Gene Therapies Advisory Committee
Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec
The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (the Committee). This meeting was announced in the Federal Register on June 30, 2026. …
Biotech-tagged tickers in the Framler universe with confirmed earnings dates. Pre-revenue biotech earnings often double as Phase 3 readouts; Framler\'s pharma-signal factor scores trial outcome probability.
No biotech tickers with confirmed earnings in the next 30 days. Finnhub typically confirms dates 4-6 weeks ahead — check back as the next quarter approaches.
Pre-revenue biotech can\'t be scored on traditional fundamentals (P/E, FCF, revenue growth). Framler runs a dedicated pharma-signal factor that ingests ClinicalTrials.gov trial state (Phase 1 / 2 / 3 / 4 + amendment count + completion proximity), classifies pharma stage (pre-revenue / early-revenue / growth / profitable), and weights the composite accordingly. NDA / BLA approval probability is computed from comparables across the trial database.